Cytokine levels in patients with non-M3 myeloid leukemia are key indicators of how well the disease responds to chemotherapy

Acute myeloid leukemia (AML) is a malignant hematological neoplastic disease. Autocrine or paracrine cytokines released by leukemic cells regulate the proliferation of AML cells. It is uncertain whether cytokines can indicate whether patients with AML are in remission with chemotherapy. The goal of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical and experimental medicine 2023-12, Vol.23 (8), p.4623-4632
Hauptverfasser: Hu, Rui, Ling, Xiaosui, Yang, Tonghua, Zhang, Jinping, Gu, Xuezhong, Li, Fan, Chen, Heng, Wen, Yan, Li, Zengzheng, Zou, Yunlian, Du, Yunyun
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Acute myeloid leukemia (AML) is a malignant hematological neoplastic disease. Autocrine or paracrine cytokines released by leukemic cells regulate the proliferation of AML cells. It is uncertain whether cytokines can indicate whether patients with AML are in remission with chemotherapy. The goal of this study was to evaluate the levels of Th1/Th2/Th17 cytokines in AML patients before and after chemotherapy to determine whether the cytokine levels could predict disease remission after chemotherapy. It was found that the levels of IL-5, IL-6, IL-8, IL-10, TNF-α, TNF-β, IL-17F, and IL-22 were significantly increased at the time of AML diagnosis in patients who achieved remission after two chemotherapy treatments ( P  
ISSN:1591-9528
1591-8890
1591-9528
DOI:10.1007/s10238-023-01242-7